STOCK TITAN

Sanara MedTech Inc. - SMTI STOCK NEWS

Welcome to our dedicated page for Sanara MedTech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara MedTech stock.

Sanara MedTech Inc. (SMTI) is a leading medical technology company that aims to revolutionize the wound care and skincare markets through innovative solutions. Founded in 1982 and headquartered in Fort Worth, Texas, Sanara MedTech focuses on developing and commercializing technologies that improve clinical outcomes for patients while simultaneously reducing healthcare costs.

The company operates through its subsidiary, Wound Care Innovations, LLC, and offers a range of collagen-based wound care products under the brand name CellerateRX. These products are marketed for treating various types of wounds, including pressure ulcers, diabetic ulcers, surgical wounds, and burns. Available in both gel and powder forms, CellerateRX is designed to serve healthcare providers such as physicians, clinics, and hospitals.

Sanara MedTech's portfolio extends beyond surgical wound care, encompassing a comprehensive suite of chronic wound care products. The company's notable offerings include HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel. These products enable Sanara MedTech to deliver extensive wound and skincare solutions across all care settings, from acute to post-acute environments.

With a strategic focus on transformative technologies, Sanara MedTech holds worldwide licenses for certain proprietary technologies and processes. This positions the company at the forefront of advancing wound care treatment protocols. Recent achievements highlight the company's commitment to innovation and quality, making it a key player in the medical technology landscape.

Sanara MedTech also prioritizes transparent communication with its investors and stakeholders. For the latest updates and developments, the company's investor relations team is readily accessible, ensuring stakeholders are well-informed about performance metrics, ongoing projects, and future prospects.

Overall, Sanara MedTech Inc. continues to set the standard in wound care and skincare solutions, contributing significantly to the healthcare sector by enhancing patient care and operational efficacy.

Rhea-AI Summary
Sanara MedTech Inc. reports strong financial results for Q4 2023 and full year 2023, with significant sales growth and operational achievements. The Company achieved record sales of $17.7 million in Q4 2023 and net revenues of $65.0 million for full year 2023, representing a 42% increase from the prior year. Sanara also announced key strategic milestones, including the acquisition of CellerateRX assets, launch of ALLOCYTE Plus product, and commercialization of BIASURGE. The Company's focus on developing transformative technologies in the medical field positions it for continued growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
-
Rhea-AI Summary
Sanara MedTech Inc. announces the release of its financial results for the quarter and year ended December 31, 2023. The company will issue its earnings release on March 25, 2024, and host a conference call on March 26, 2024, to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
-
Rhea-AI Summary
Sanara MedTech Inc. announces unaudited preliminary results for Q4 and full-year 2023, showing a 15.5% increase in net revenue for Q4 and a 41.8% increase for the full year. Cash position stands at $5.1 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
Rhea-AI Summary
Sanara MedTech Inc. (NASDAQ: SMTI) has signed an exclusive license agreement with Tufts University to develop and commercialize patented technology covering 18 unique collagen peptides. The agreement includes one U.S. patent, one granted European patent, one Canadian patent pending, and one Patent Cooperation Treaty patent pending. Sanara has formed a new subsidiary, Sanara Collagen Peptides, LLC, and has issued 10% of SCP’s outstanding units to Tufts. SCP has exclusive rights to develop and commercialize new products based on the licensed patents and patents pending. SCP will pay royalties to Tufts based on net sales of licensed products and technologies. The company aims to expand its product offering of collagen products and sees significant opportunities to improve outcomes and advance patient care while reducing healthcare system costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
none
-
Rhea-AI Summary
Sanara MedTech Inc. (NASDAQ: SMTI) announced the publication of a retrospective study on CellerateRX Surgical Powder in the Journal of Surgery. The study demonstrates the significant impact of CellerateRX in reducing surgical site infections and promoting wound healing in elective surgery patients. Sanara's CEO believes that these results align with the company's mission of improving outcomes while lowering costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
Rhea-AI Summary
Sanara MedTech Inc. (NASDAQ: SMTI) announced its strategic, operational, and financial results for Q3 2023, including record sales, narrowing net loss, and positive Adjusted EBITDA. The company completed the acquisition of collagen business assets and launched ALLOCYTE Plus and BIASURGE products. Net revenue for Q3 2023 was $16.0 million, a 23% increase from the prior year period. The Company's loss before income taxes for Q3 2023 was $1.1 million compared to $3.2 million in Q3 2022. Adjusted EBITDA was $0.3 million for Q3 2023 compared to negative $1.6 million in Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.36%
Tags
Rhea-AI Summary
Sanara MedTech Inc. announced details for the release of its Q3 2023 results. The earnings release will be on November 13, 2023, followed by a conference call on November 14, 2023. The company's focus is on developing and commercializing transformative technologies in the medical field. Investors can access the conference call through a toll-free number or a live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
-
Rhea-AI Summary
Sanara MedTech announces first sale of ALLOCYTE Plus and provides updates on BIASURGE
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
none
-
Rhea-AI Summary
Sanara MedTech CEO to present at MicroCapClub Leadership Summit and Cantor Fitzgerald Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.71%
Tags

FAQ

What is the current stock price of Sanara MedTech (SMTI)?

The current stock price of Sanara MedTech (SMTI) is $33.68 as of December 20, 2024.

What is the market cap of Sanara MedTech (SMTI)?

The market cap of Sanara MedTech (SMTI) is approximately 279.5M.

What is Sanara MedTech Inc. known for?

Sanara MedTech Inc. is known for developing and commercializing innovative wound care and skincare technologies.

What products does Sanara MedTech offer?

Sanara MedTech offers CellerateRX Surgical Activated Collagen, HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.

Who are the primary customers for Sanara MedTech's products?

The primary customers include healthcare providers such as physicians, clinics, and hospitals.

Where is Sanara MedTech Inc. headquartered?

Sanara MedTech Inc. is headquartered in Fort Worth, Texas.

When was Sanara MedTech Inc. founded?

Sanara MedTech Inc. was founded in 1982.

How does Sanara MedTech contribute to healthcare cost reduction?

Sanara MedTech contributes to healthcare cost reduction by improving clinical outcomes with its innovative wound care and skincare technologies.

What forms does CellerateRX come in?

CellerateRX is available in gel and powder forms.

What conditions can CellerateRX treat?

CellerateRX treats pressure ulcers, diabetic ulcers, surgical wounds, burns, and more.

How does Sanara MedTech ensure transparent communication with investors?

Sanara MedTech ensures transparent communication through regular updates and accessible investor relations contacts.

Who is the current Director of Investor Relations at Sanara MedTech?

Callon Nichols is the current Director of Investor Relations at Sanara MedTech.

Sanara MedTech Inc.

Nasdaq:SMTI

SMTI Rankings

SMTI Stock Data

279.45M
2.92M
66.56%
9.42%
2.37%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
FORT WORTH